NCT03730519View on ClinicalTrials.gov

UK Registry for Baroreflex Activation Therapy

NATerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2021

Conditions
Baroreflex Failure SyndromeHypertension, Resistant to Conventional Therapy
Interventions
DEVICE

Baroreflex Activation Therapy with Barostim Neo

Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.

Trial Locations (1)

EC1M 6BQ

William Harvey Research Institute, London

Sponsors

Collaborators (1)

CVRx, Inc.
All Listed Sponsors
collaborator

CVRx, Inc.

INDUSTRY

lead

Queen Mary University of London

OTHER

NCT03730519 - UK Registry for Baroreflex Activation Therapy | Biotech Hunter | Biotech Hunter